Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.45 |
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | CCR8 | P51685 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463497 | 0.79 | NOS2 (0.63) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL27654710 | 0.78 | NOS2 (0.42) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL305502 | 0.77 | NOS2 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL31150926 | 0.77 | NOS2 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL3294193 | 0.77 | NOS2 (0.50) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL27964282 | 0.77 | NOS2 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL13059144 | 0.77 | NOS2 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| SCHEMBL5009720 | 0.77 | NOS2 (0.45) | NOS2NOS3CCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL3899633 | 0.76 | NOS2 (0.44) | NOS2NOS3CCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL5012207 | 0.76 | NOS2 (0.48) | NOS2NOS3CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452008-B2 | 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2001-12-13 | — | — | US | disclosed |
| US-6300500-B1 | Preparation of pyridone derivatives using phthalimido containing starting material | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1086948-A1 | PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | HK1, HPD, ALK | NOS2 4721/4885NOS3 4645/4885CCR1 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.